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Head and neck squamous cell carcinoma (HNSCC) 
develops from the mucosal linings of the upper 
aerodigestive tract, comprising 1) the nasal cavity and 
paranasal sinuses, 2) the nasopharynx, 3) the 
hypopharynx, larynx, and trachea, and 4) the oral 
cavity and oropharynx. Squamous cell carcinoma 
(SCC) is the most frequent malignant tumor of the head 
and neck region. HNSCC is the sixth leading cancer by 
incidence worldwide. There are 500000 new cases a 
year worldwide. Two thirds occur in industrialized 
nations. HNSCC usually develops in males in the 6th 
and 7th decade. It is caused by tobacco and alcohol 
consumption and infection with high-risk types of 
human papillomavirus (HPV). SCC often develops 
from preexisting dysplastic lesions. The five-year 
survival rate of patients with HNSCC is about 40-50%. 
Classification 
SCC can occur either in 1) the nasal cavity and 
paranasal sinuses, 2) the nasopharynx, 3) the 
hypopharynx, larynx, and trachea, or 4) the oral cavity 
and oropharynx. The 2005 World Health Organization 
(WHO) classification of Head and Neck Tumors 




- Basaloid  
- Papillary 
- Spindle cell (sarcomatoid)  
- Acantholytic  
- Adenosquamous 
- Cuniculatum 
Each variant can arise in any one of the 4 above 
mentioned head and neck regions, except for the 
cuniculatum type which only develops from the oral 
mucosa.  
SCC can be well-, moderately- or poorly-differentiated, 
and either keratinizing or non-keratinizing. Most cases 
are moderately to poorly-differentiated.  
Precursor lesions (dysplasia) can be (arbitrarily) 
separated into mild, moderate, or severe (carcinoma in 
situ) (see below). 
Clinics and pathology 
Etiology 
The most important risk factors for developing HNSCC 
are tobacco smoking and alcohol consumption, which 
have a synergistic effect. Smoking habits that increase 
the risk of developing HNSCC are smoking black 
tobacco (compared to blond tobacco), smoking at a 
young age, long duration, high number of cigarettes per 
day, and deep smoke inhalation (Benhamou et al., 
1992). Avoiding cigarettes and alcohol could prevent 
about 90% of HNSCCs, especially laryngeal and 
hypopharyngeal tumors. Tobacco chewing is a major 
cause of oral and oropharyngeal SCC in the Indian 
subcontinent, parts of South-East Asia, China and 
Taiwan, especially when consumed in betel quids 
containing areca nut (Znaor et al., 2003). In India, 
chewing accounts for nearly 50% of oral and 
oropharyngeal tumors in men and over 90% in women 
(Barnes et al., 2005). Significant risk increases of 
developing HNSCC have also been reported among 
non-drinking smokers and, to a lesser extent, non-
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smoking heavy drinkers. Heavy consumption of all 
types of alcoholic beverages (wine, beer, hard liquors) 
confers an increased risk (La Vecchia et al., 1999). 
Conversely, protective effects of diets rich in fresh 
fruits and vegetables have been described (Pelucchi et 
al., 2003). 
Some occupational exposures may be associated with a 
higher risk of developing HNSCC, especially of the 
larynx: polycyclic aromatic hydrocarbons, metal dust, 
cement dust, varnish, lacquer, etc... Significant 
associations were also found with ionizing radiation, 
diesel exhausts, sulphuric acid mists, and mustard g s 
(Barnes et al., 2005). 
The incidence of HNSCC in specific sites has been 
slowly declining during the past decade, due to a 
decrease in the prevalence of the more traditional risk 
factors, most notably smoking. However, in the 
Western World, HNSCCs, notably of the oral cavity 
and oropharynx, are becoming more prevalent, which 
may be related to an increase in oral and oropharyngeal 
HPV infections (Leeman et al., 2011). Indeed, recent 
studies have shown that infection with high-risk types 
of HPV (e.g. HPV-16 and -18) is responsible for a 
subgroup of HNSCCs. HPV-positive tumors represent 
a different clinicopathological and molecular entity 
compared to HPV-negative cases (see below). HPV 
infection is now recognized as one of the primary 
causes of oropharyngeal SCC (especially SCC of the 
tonsils and the base of the tongue). In the USA, about 
40-80% of oropharyngeal cancers are caused by HPV, 
whereas in Europe the proportion varies from around 
90% in Sweden to less than 20% in communities with 
the highest tobacco use (Marur et al., 2010). Patients 
tend to be younger, with no prior history of tobacco 
and/or heavy alcohol consumption. There is evidence 
that HPV-positive HNSCC is a sexually transmitted 
disease. A strong association between sexual behavior 
(oral sex) and risk of oropharyngeal cancer as wellas 
HPV-16-positive HNSCC has been demonstrated 
(Smith et al., 2004; Gillison et al., 2008). 
Finally, certain inherited disorders, such as Fanconi 
anemia or Bloom syndrome, predispose to HNSCC 
(Kutler et al., 2003; Barnes et al., 2005). 
Epidemiology 
SCC is the most frequent malignant tumor of the head 
and neck region. HNSCC represents the sixth leading 
cancer by incidence and there are 500000 new cases a 
year worldwide (Kamangar et al., 2006). Two thirds 
occur in industrialized nations. Most HNSCCs arise in 
the hypopharynx, larynx, and trachea, and in the oral
cavity and oropharynx. The majority of laryngeal SCCs 
originate from the supraglottic and glottic regions. 
Tracheal SCCs are rare compared to laryngeal ones. 
The most common oropharyngeal site of involvement  
is the base of the tongue. Within the oral cavity, most 
tumors arise from the floor of the mouth, the 
ventrolateral tongue or the soft palate complex. 
HNSCCs occur most frequently in the sixth and 
seventh decades. They typically develop in men thoug  
women are more and more affected because of 
increased prevalence of smoking over the last two 
decades (Barnes et al., 2005). For laryngeal, 
hypopharyngeal and tracheal SCCs, the incidence in 
men is high in Southern and Central Europe, some parts
of South America, and among Blacks in the United 
States. The lowest rates are recorded in South-East 
Asia and Central Africa. The disease is slightly more 
common in urban than in rural areas. For oral and 
oropharyngeal SCCs, the disease usually affects adults 
in the 5th and 6th decades of life. Extremely elevated 
rates are observed in France, parts of Switzerland, 
Northern Italy, Central and Eastern Europe, and parts 
of Latin America. Rates are high among both men and 
women throughout South Asia. In the US, incidence 
rates are two-fold higher in Blacks compared to Whites 
(Barnes et al., 2005). 
Clinics 
Clinical features of HNSCC depend on the localization 
of the tumor. 
Nasal and paranasal sinuses 
Patients with SCC arising in the nasal or paranasal 
sinuses may complain of nasal fullness, stuffiness, or 
obstruction, but also of epistaxis, rhinorrhea, pain, 
paraesthesia, swelling of the nose and cheek or of a
palatal bulge. Some may present with a persistent or 
non-healing nasal sore or ulcer, a nasal mass, or in 
advanced cases, proptosis, diplopia, or lacrimation 
(Barnes et al., 2005; Thompson, 2006). 
Nasopharynx 
Most patients with nasopharyngeal carcinoma present 
with painless enlargement of upper cervical lymph 
nodes. Nasal symptoms, particularly blood-stained 
post-nasal drip are reported in half the cases. Serous 
otitis media following Eustachian tube obstruction is 
also common. Headaches and cranial nerve 
involvement indicate more advanced disease. However, 
10% of the patients are asymptomatic (Barnes et al., 
2005; Thompson, 2006). 
Hypopharynx, larynx, and trachea 
Hypopharyngeal and supraglottic tumors may be 
responsible of dysphagia, change in quality of voice, 
foreign body sensation in the throat, haemoptysis, and 
odynophagia. Glottic SCC most commonly presents 
with hoarseness (Fig. 1). In case of subglottic tumor, 
dyspnea and stridor are frequent clinical features. SCC 
arising in the trachea may cause dyspnea, wheezing or 
stridor, acute respiratory failure, cough, haemoptysis, 
and hoarseness (Barnes et al., 2005; Thompson, 2006). 
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Figure 1: Endoscopy. Exophytic and ulcerative SCC of the left vocal cord. Figure 2: Large exophytic and ulcerative SCC of the left 
amygdala. Fig. 1-2 were kindly provided by Dr S. Hans (Georges Pompidou European Hospital, Paris, France). 
 
Oral cavity and oropharynx 
Most patients display at the time of diagnosis sign a d 
symptoms of locally advanced disease. Clinical 
features vary according to the exact site of the lesion. 
The most common presenting features are ulceration, 
pain, referred pain to the ear, difficulty with speaking, 
opening the mouth or chewing, difficulty and pain with 
swallowing, bleeding, weight loss, and neck swelling 
(Fig. 2). Cancer of the buccal mucosa may present as 
an ulcer with indurated raised margins or as an 
exophytic growth. SCC of the floor of the mouth may 
arise as a red or ulcerated lesion or as a papillary 
growth. Cancer of the gingiva usually presents as an 
ulceroproliferative growth. Cancer of the tongue may 
appear as an ulcer infiltrating deeply and reducing the 
mobility of the tongue. SCC of the base of the tongue 
usually presents at a locally advanced stage as an 
ulcerated, painful, indurated growth. Cancer of the hard 
palate often presents as a papillary or exophytic growth 
rather than a flat or ulcerated lesion. Cancer of soft
palate and uvula often appears as an ulcerative lesion 
with raised margins or as a fungating mass. 
Occasionally, patients harbor enlarged cervical lymph 
nodes with no identifiable oral or oropharyngeal lesion. 
In very advanced disease, patients may present an 
ulceroproliferative lesion with areas of necrosis and 
extension to surrounding structures, such bone, muscle 
and skin (Barnes et al., 2005; Thompson, 2006). 
Pathology 
Precursor lesions 
The 2005 WHO classification of precursor lesions 
(Barnes et al., 2005) is as follows: 
- Squamous cell hyperplasia 
Hyperplasia describes increased cell numbers. This 
may be in the spinous layer (acanthosis) and/or in the 
basal/parabasal cell layers (progenitor compartment), 
termed basal cell hyperplasia. The architecture show  
regular stratification without cellular atypia. 
- Mild dysplasia (Squamous Intraepithelial Neoplasia 
(SIN) 1) 
- Moderate dysplasia (SIN 2) 
- Severe dysplasia (SIN 3) 
- Carcinoma in situ (SIN 3) 
The Ljubljana classification of squamous intraepithelial 























SIN 2 Atypical hyperplasia 
Severe 
dysplasia 
SIN 3 Atypical hyperplasia 
Carcinoma in 
situ 
SIN 3 Carcinoma in situ 
 
Invasive HNSCCs arise in most cases from 
preneoplastic lesions grouped under the term 
"dysplasia". Dysplastic lesions present with an 
increased likelihood of progressing to SCC. The altred 
epithelium displays architectural and cytological 
changes that range from mild to severe (see below). 
Precursor lesions are mostly seen in the adult 
population and affect men more often than women. 
They are strongly associated with tobacco smoking and 
alcohol consumption, and especially a combination of 
the two. The duration of smoking, the type of tobacco 
and the practice of deep inhalation play a role in the 
development of precursor lesions. Other etiological 
factors have been reported such as industrial pollution, 
specific occupational exposures, and nutritional 
deficiency. Mean age of patients with first diagnosis of 
precursor lesions is 48-56.5 years. Rarely, malignant 
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transformation may develop from morphologically 
normal epithelium (Barnes et al., 2005; Thompson, 
2006). 
The clinical picture of precursor lesions depends on the 
location and severity of the disease. In case of 
dysplastic lesions of the hypopharynx, larynx or 
trachea, patients may present with fluctuating 
hoarseness, sore throat, and/or chronic cough of a few 
months' duration. However, some individuals may be 
asymptomatic. 
Endoscopically, the lesions may be discrete or diffuse, 
smooth or irregular, flat or exophytic. Precursor lesions 
may present as a small flat patch or as a large warty 
plaque. The surface may be brown to red 
(erythroplakia) or present with circumscribed whitish 
plaques (leukoplakia). White patches may be ulcerated. 
Leukoplakia, in contrast to erythroplakia, tends to be 
well demarcated and seems to have a lower risk of 
malignant transformation. The lesions are commonly 
diffuse, with a thickened appearance. However, in a 
minority of cases, patchy atrophy may be present. In 
the larynx, the precursor lesions appear mainly along 
the anterior true vocal cords. Two thirds of vocal ord 
lesions are bilateral. Occasionally, precursor lesion  
may present macroscopically as normal mucosa 
(Barnes et al., 2005; Thompson, 2006). 
Microscopically, dysplasia is defined as architectural 
and cytological changes of the epithelium, without 
evidence of invasion. The diagnostic features of 
dysplasia are not uniformly accepted or interpreted. In 
dysplastic lesions, the epithelium presents with 
irregular stratification, loss of polarity of basal cells, 
drop-shaped rete ridges, increased number of mitotic 
figures, abnormal superficial mitoses, premature 
keratinization in single cells (dyskeratosis) and keratin 
pearls within rete pegs. Cytological changes include 
abnormal variation in nuclear or cell size and shape, 
increased nuclear to cytoplasmic ratio, increased 
nuclear size, atypical mitotic figures, increased number 
and size of nucleoli, and hyperchromasia. The spectrum 
of dysplasia is divided for practical reasons into mild, 
moderate and severe. In mild dysplasia, architectural 
disturbances and cytological atypia are limited to the
lower third of the epithelium. In moderate dysplasia, 
architectural and cytological changes extend into the 
middle third of the epithelium. Up-grading from 
moderate to severe dysplasia may be considered when
there is marked cytological atypia. Severe dysplasia 
displays greater than two thirds altered epithelium. 
Carcinoma in situ presents with full thickness or almost 
full thickness architectural abnormalities accompanied 
by cytological atypia (Fig.3). Superficial and atypical 
mitotic figures are commonly seen. By definition, 
invasion has not yet occurred. Differential diagnosis of 
dysplastic lesions includes reactive or regenerative 




Conventional type squamous cell carcinoma 
SCC is characterized by squamous differentiation 
(often seen as keratinization, sometimes with keratin 
pearl formation) and invasive growth with disruption f 
the basement membrane. Extension into the underlying 
tissue is often accompanied by a desmoplastic stromal 
reaction and a dense inflammatory infiltrate, mainly 
comprised of lymphocytes and plasma cells. 
Angiolymphatic and perineural invasion may be seen. 
SCC is graded into well-, moderately-, and poorly-
differentiated. Well-differentiated SCC closely 
resembles normal squamous mucosa whereas 
moderately-differentiated SCC displays nuclear 
pleomorphism, mitoses (including atypical forms), and 
usually less keratinization (Fig. 4-6). In poorly-
differentiated SCC, immature cells predominate, with 
numerous typical and atypical mitoses, minimal 
keratinization, and sometimes necrosis. Most SCCs are 
moderately-differentiated (Barnes et al., 2005; 
Thompson, 2006). 
HNSCCs express epithelial markers such as 
cytokeratins. In well-differentiated tumors, no 
additional stains are usually needed. In poorly-
differentiated lesions, immunohistochemistry may be 
useful. HNSCCs are immunopositive for cytokeratin 
cocktails, AE1/AE3 and pancytokeratin. CK5/CK6 and 
p63 are also excellent markers to detect squamous 
differentiation (Dabbs, 2006). 
Verrucous carcinoma 
Verrucous carcinoma (VC) is a non-metastasizing 
variant of well-differentiated SCC characterized by an 
exophytic, warty, slowly-growing tumor with pushing 
rather than infiltrative margins (Barnes et al., 2005). 
The larynx is the second most common site of VC in 
the head and neck region after the oral cavity. The
gross appearance is of a broad-based, exophytic, warty, 
firm to hard, white mass. Microscopically, the 
thickened, club-shaped, projections are lined by well-
differentiated squamous epithelium devoid of the 
malignant features commonly seen in SCC. Mitotic 
figures are rare and not atypical. The advancing 
margins are usually broad with a pushing appearance. 
A dense inflammatory response is often present in the 
underlying tissue. There is abundant surface keratosis 
("church-spire" keratosis) (Fig. 7). Differential 
diagnosis includes verrucous hyperplasia and very 
well-differentiated SCC. Distinguishing these entities 
from verrucous carcinoma can be delicate. Analysis of 
a sample of sufficient size which has been accurately 
oriented is necessary before rendering a definitive 
diagnosis. The separation of verrucous hyperplasia 
from verrucous carcinoma is often difficult, requiring 
clinical-pathological confrontation. Pure VC does not 
metastasize and has an excellent prognosis. However, 
hybrid VC (displaying a conventional SCC component) 
has the potential to metastasize and should be managed 
as similarly staged SCC (Barnes et al., 2005; 
Thompson, 2006). 
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Basaloid squamous cell carcinoma 
Basaloid squamous cell carcinoma is a high-grade 
variant of SCC composed of both basaloid and 
squamous components (Barnes et al., 2005). It is an 
aggressive, rapidly growing tumor characterized by an 
advanced stage at the time of diagnosis (cervical lymph 
node metastases) and a poor prognosis. The basaloid 
component is comprised of small packed cells 
displaying hyperchromatic nuclei without nucleoli, and 
scant cytoplasm. The tumor grows in a solid pattern 
with a lobular configuration, and sometimes a 
prominent peripheral palisading. Comedo-type necrosis 
is frequently seen (Fig. 8). Small cystic spaces 
containing PAS- and Alcian Blue-positive material and 
stromal hyalinization may be noticed. BSCC is always 
associated with a SCC component, usually located 
superficially. The SCC component may also present as 
focal squamous differentiation within the basaloid 
lobules. The junction between the two components may 
be abrupt. The differential diagnosis includes 
neuroendocrine carcinoma, adenoid cystic carcinoma, 
and adenosquamous carcinoma. BSCC requires 
aggressive multimodality treatment, including radicl 
surgery (including neck dissection), radiotherapy, and 
chemotherapy (especially for metastatic disease). 
Survival rate is only 40% (Thompson, 2006). 
Papillary squamous cell carcinoma 
Papillary squamous cell carcinoma (PSCC) is a distinct 
variant of SCC characterized by an exophytic, papill ry 
growth, and a favorable prognosis. PSCC presents as a 
soft, friable, polypoid, exophytic, papillary tumor. It 
frequently arises from a thin stalk, but broad-based 
lesions have also been described. The tumor is 
characterized by a predominant papillary growth 
pattern. By definition, the lesion must demonstrate  
dominant (> 70%) exophytic or papillary architectural 
growth pattern with unequivocal cytological evidenc 
of malignancy. The papillary pattern consists of 
multiple, thin, delicate, finger-like papillary 
projections. These papillae have thin fibrovascular 
cores covered by neoplastic, immature basaloid cells or 
more pleomorphic cells. Commonly, there is minimal 
keratosis. Foci of necrosis and hemorrhage are 
common. Invasion may be difficult to define, especially 
in superficial biopsies. Stroma invasion consists of a 
single or multiple nests of tumor cells with dense 
lymphoplasmacytic inflammation at the tumor-stroma 
interface. Differential diagnosis includes squamous 
papilloma, verrucous carcinoma, and exophytic SCC. 
Though squamous papilloma and verrucous carcinoma 
share similar architectural features with PSCC, the
latter is easily recognized by atypia of the squamous 
epithelium. Patients with PSCC tend to have a better 
prognosis compared to those with site- and stage-
matched conventional SCC. This is probably related to 
limited invasion in PSCC. Approximately, one third of 
patients develop recurrence, frequently more than once 
(Barnes et al., 2005; Thompson, 2006). 
Spindle cell carcinoma 
Spindle cell carcinoma is a biphasic tumor composed of 
a squamous cell carcinoma, either in situ and/or 
invasive, and a malignant spindle cell component with 
a mesenchymal appearance, but of epithelial origin 
(Barnes et al., 2005). Spindle cell carcinoma most often 
occurs in males. It usually exhibits a polypoid 
appearance with a mean size of 2 cm. The surface is 
frequently ulcerated. The spindle cell component 
usually forms the bulk of the tumor. It can be arranged 
in a diverse array of appearances, including storiform, 
interlacing bundles or fascicles, and herringbone. The
two components can abut directly against one another 
with areas of blending and continuity between them. 
Hypocellular areas with dense collagen deposition ca  
be seen. Pleomorphism is often mild to moderate, 
without a severe degree of anaplasia. The tumor cells
are plump fusiform cells, although they can be rounded 
and epithelioid. Rarely, metaplastic or frankly 
neoplastic cartilage or bone can be seen. Resemblance 
to fibrosarcoma or malignant fibrous histiocytoma is 
most common. Evidence for squamous epithelial 
derivation can be seen as either in situ carcinoma r s 
invasive SCC. The SCC component is usually minor to 
inconspicuous with the sarcomatoid part dominating. 
Carcinoma in situ can be obscured by extensive 
ulceration. Infiltrating SCC may be focal, requiring 
multiple sections for demonstration. Sometimes, only 
spindle cells are present; in such cases, SPCC can be 
mistaken for a true sarcoma. Metastases usually contain 
SCC alone or both SCC and the spindle cell 
component, and rarely, only the spindle cell 
component. SPCC can also be confused with reactive 
or benign spindle cell proliferation (such as nodular 
fasciitis), inflammatory myofibroblastic sarcoma, low-
grade myofibroblastic sarcoma, and myoepithelial 
carcinoma. There is mounting molecular evidence that 
SPCC is a monoclonal epithelial neoplasm with a 
divergent (mesenchymal) differentiation, rather than a 
collision tumor. This is the one SCC variant in which 
immunohistochemistry may be of value. The individual 
neoplastic spindle cells react variably with keratin 
(AE1/AE3), EMA, and CK18, even though only 70% 
of cases will yield any epithelial immunoreactivity. A 
nonreactive or negative result should not dissuade the 
pathologist from the diagnosis, especially in the right 
setting. Spindle cell carcinoma metastasizes to the 
regional lymph nodes in up to 25% of cases, but distant 
dissemination is less common (5-15%). The reported 5-
year survival rate is between 65% and 95% (Barnes et 
al., 2005; Thompson, 2006). 
Acantholytic squamous cell carcinoma 
This is an uncommon histopathologic variant of 
squamous cell carcinoma, characterized by acantholysis 
of the tumor cells, creating pseudolumina and false 
appearance of glandular differentiation. No special 
etiologic factor has been discovered for the mucosal 
acantholytic SCC. It is most frequent in sun-exposed 
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areas of the head and neck. The tumor is composed of 
SCC, but with foci of acantholysis in tumor nests, 
creating the appearance of glandular differentiation. 
The pseudolumina usually contain acantholytic and 
dyskeratotic cells, or cellular debris, but they may be 
empty. They are more frequent in the deeper portions 
of the tumor. There is no evidence of true glandular 
differentiation or mucin production. The SCC 
component predominates, and is usually moderately-
differentiated. The stroma is usually desmoplastic, w th 
a lymphoplasmacytic response. The acantholysis may 
also form anastomosing spaces and channels 
mimicking angiosarcoma. Acantholytic SCC must be 
differentiated from adenosquamous carcinoma, adenoi 
cystic carcinoma, and mucoepidermoid carcinoma. 
Prognosis is similar to that of SCC. However, some 
reports suggest a more aggressive behavior (Barnes et 
al., 2005; Thompson, 2006). 
Adenosquamous carcinoma 
This rare aggressive neoplasm originates from the 
surface epithelium and is characterized by both 
squamous cell carcinoma and true adenocarcinoma. 
The larynx is the most frequent site of occurrence. 
Most patients (65%) present with lymph node 
metastases. Adenosquamous carcinoma occurs 
throughout the upper aerodigestive tract, often as an 
indurated submucosal nodule usually less than 1 cm in 
diameter. It can present as an exophytic or polypoid 
mass, or as poorly defined mucosal induration, 
frequently with ulceration. The main feature is both 
true adenocarcinoma and SCC. The two components 
occur in close proximity, but they tend to be distinc  
and separate, not intermingled as in mucoepidermoid 
carcinoma. The SCC component can present either as 
in situ or as an invasive SCC. The adenocarcinomatous 
component tends to occur in the deeper parts of the 
tumor. It consists of tubular structures that give ris  to 
"glands within glands". The adenocarcinoma 
component can be tubular, alveolar, and glandular, 
although mucus-cell differentiation is not essential for 
the diagnosis. Mucin production is typically present, 
either intraluminal or intracellular, and can appear as 
signet ring cells. There is typically a sparse 
inflammatory cell infiltrate at the tumor-stroma 
interface. Differential diagnosis includes 
mucoepidermoid carcinoma, acantholytic SCC, and 
SCC invading seromucinous glands, and necrotizing 
sialometaplasia. The most important differential 
diagnosis is from mucoepidermoid carcinoma as 
adenosquamous carcinoma has a poorer prognosis. 
Aggressive surgery with neck dissection yields an 
approximately 55% 2-year survival rate (Barnes et al., 
2005; Thompson, 2006). 
Carcinoma cuniculatum is a rare variant of oral 
cancer displaying similarities with lesions more 
commonly described in the foot in which the tumor 
infiltrates deeply into the bone. There is proliferation of 
stratified squamous epithelium in broad processes with 
keratin cores and keratin-filled crypts which seem to 
burrow into bone tissue, but lack obvious cytological 
features of malignancy. Clinical-pathological 
correlation is often needed to make the diagnosis 
(Barnes et al., 2005). 
Nasopharyngeal carcinoma and lymphoepithelial 
carcinoma are rare entities distinct from conventional 
squamous cell carcinomas. Lymphoepithelial 
carcinoma (LEC) may develop in the nasal cavity and
paranasal sinuses, the hypopharynx, larynx and trachea, 
and in the oral cavity and oropharynx. It is a poorly 
differentiated squamous cell carcinoma or 
histologically undifferentiated carcinoma accompanied 
by a prominent reactive lymphoplasmacytic infiltrate, 
morphologically similar to nasopharyngeal carcinoma. 
Most sinonasal LECs are associated with Epstein-Barr 
virus (EBV) infection (Barnes et al., 2005). 
Nasopharyngeal carcinoma (NPC) is a carcinoma 
arising in the nasopharynx that shows light microscopi  
or ultrastructural evidence of squamous differentiation. 
It encompasses squamous cell carcinoma, non-
keratinizing carcinoma (differentiated or 
undifferentiated), and basaloid squamous cell 
carcinoma. Keratinizing squamous cell carcinoma of 
the nasopharynx is morphologically similar to 
keratinizing squamous cell carcinomas occurring in 
other head and neck sites. NPC incidence is 
considerably higher in Chinese, Southeast Asians, 
North Africans, and native people from the Arctic 
region. There is a near constant association of NPC 
with EBV, suggesting an oncogenic role of the virus. 
NPC harbors a highly malignant behavior with 
extensive loco-regional infiltration, early lymphatic 
spread, and hematogenous dissemination (Barnes et al.,
2005). 
Histogenesis 
SCC originates from the squamous mucosa or from 
ciliated respiratory epithelium that has undergone 
squamous metaplasia (Barnes et al., 2005). 
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Figure 3: Carcinoma in situ. Full thickness architectural abnormalities and cytological atypia Hematoxylin and eosin staining (original 
magnification x200). Figure 4: Invasive SCC. Invasive growth with disruption of the basement membrane and extension into the 
underlying tissue. Hematoxylin and eosin staining (original magnification Fig. 4A: x20, Fig. 4B: x100). Figure 5: Invasive SCC. Mitoses 
(at 9 o' clock) and nuclear atypia. Hematoxylin and eosin staining (original magnification x400). Figure 6: Invasive SCC. Focal 
keratinization (left hand side). Hematoxylin and eosin staining (original magnification x400). Figure 7: Verrucous carcinoma. Thickened, 
club-shaped, projections of well-differentiated squamous epithelium and abundant surface keratosis ("church-spire" keratosis). 
Hematoxylin and eosin staining (original magnification x20). Figure 8: Basaloid SCC. Solid pattern of growth and central comedo-type 
necrosis. Hematoxylin and eosin staining (original magnification x100). Figure 9: p16 immunostaining in basaloid SCC (original 
magnification x200). 
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Cytogenetics 
Precursor lesions 
Malignant transformation of the mucosal lining is a 
genetic process resulting from accumulation of multiple 
genetic alterations that dictates the frequency and pace 
of progression to invasive carcinoma. LOH studies 
indicate that the earliest alterations appear to targe  
specific genes located on chromosomes 3p, 9p21 
(CDKN2A), and 17p13 (TP53). Alterations that tend to 
occur in association with higher grades of dysplasia nd 
SCC include cyclin D1 amplification, PTEN 
inactivation, and LOH at 13q21, 14q32, 6p, 8, 4q27, 
and 10q23 (Barnes et al., 2005). 
There are no individual markers that reliably predict 
malignant transformation of dysplastic lesions. Ploidy 
studies of dysplastic leukoplakias showed that the great 
majority of aneuploid lesions developed SCC in the 
follow-up period, by contrast with 60% of tetraploid 
lesions and only about 3% of diploid lesions (Sudbo et 
al., 2001). Similar studies on erythroplakias confirmed 
the higher predictive potential of aneuploidy in 
identifying cases which progressed to SCC (Sudbo et 
al., 2002). 
Invasive squamous cell carcinoma 
HNSCC is a heterogeneous disease, comprising at least 
two distinct genetic subclasses: tumors that are caused 
by infection with high-risk types of HPV, and those 
that do not contain HPV. Approximately 20% of 
HNSCCs contain transcriptionally active HPV whereas 
60% harbor a TP53 mutation. In the remaining 20%, 
other genes encoding proteins in the p53 pathway may 
be targeted or these tumors may undergo p53-
independent malignant progression. 
- HPV-negative squamous cell carcinoma 
Tobacco and alcohol-induced HNSCCs are 
characterized by TP53 mutation. The excess of G to T 
transversions and the codons more frequently affected 
were attributed to the carcinogenic effect of tobacco 
smoking (Barnes et al., 2005). Other genes are involved 
in the pathogenesis of HPV-negative tumors. CCND1, 
which encodes cyclin D1, is amplified or gained in 
more than 80% of HPV-negative HNSCCs. CDKN2A 
(encoding p16) can be inactivated by mutation, 
homozygous deletion, or promoter hypermethylation 
(Barnes et al., 2005). 
EGFR (Epidermal Growth Factor Receptor) is 
overexpressed in most HNSCCs (Hama et al., 2009). 
The EGFR is a receptor tyrosine kinase belonging to 
the erbB family of cell surface receptors. Once 
phosphorylated, it can signal through MAPK, Akt, 
ERK, and Jak/STAT pathways. These pathways are 
related to cellular proliferation, apoptosis, invasion, 
angiogenesis, and metastasis. Dysfunction of the 
receptor and its associated pathways occurs in 80-90% 
of HNSCCs (Kalyankrishna et al., 2006). Mutations 
and amplifications of EGFR have been reported, albeit 
at relatively low frequencies. EGFR amplification has 
been detected in 10-30% of cases (Temam et al., 2007; 
Sheu et al., 2009). Even though few activating 
mutations have been found, the mutant form EGFRvIII 
has been detected in 42% of HNSCCs (Sok et al., 
2006). Interestingly, it has been shown that 
microscopically normal mucosa adjacent to invasive 
SCC displayed a high degree of overexpression and 
that the upregulation of EGFR occurs in the transition 
from dysplasia to cancer (Grandis et al., 1993; Shin et 
al., 1994). Elevated levels of EGFR expression have 
been associated to a poor clinical outcome (Chung et 
al., 2004; Temam et al., 2007). High copy number 
amplification has also been shown to portend a dismal 
prognosis in HNSCCs (Chung et al., 2006). However, 
overexpression of EGFR may be a biomarker for an 
improved response to therapy and could serve as a 
predictive marker (Bentzen et al., 2005). The EGFR 
pathway can be targeted through the use of specific 
tyrosine kinase inhibitors (TKIs), monoclonal 
antibodies blocking receptor dimerization, and anti-
sense oligodeoxynucleotides or siRNA blocking 
mRNA expression (Glazer et al., 2009). 
Both mutations and gene amplifications of MET have 
been described in HNSCCs. MET, the receptor for 
Hepatocyte Growth Factor (HGF) is a tyrosine kinase 
encoded by MET on chromosome 7q31. It activates the 
AKT and Ras pathways and influences growth, motility 
and angiogenesis in HNSCCs (Leeman et al., 2011). 
Finally, the PI3K-PTEN-AKT pathway is frequently 
activated in HNSCCs (Leeman et al., 2011). 
- HPV-induced squamous cell carcinoma 
HPVs are DNA viruses that show a tropism for 
squamous epithelium. HPV is a strictly epitheliotropic, 
circular double-stranded DNA virus. There are more 
than 100 subtypes of HPV, some of which are involved 
in cervical carcinogenesis and have been designated as 
high-risk HPVs (e.g. HPV-16 and -18) (zur Hausen, 
2002; Moody et al., 2010). HPV-positive HNSCCs 
present with distinct molecular profiles compared to 
HPV-negative tumors whereas they harbor similarities 
with HPV-positive cervical SCCs. Most HPV-induced 
HNSCCs are caused by one subtype, HPV-16. HPV 
infection is an early, and probably initiating, oncgenic 
event in HNSCCs. High-risk oncogenic HPV subtypes 
have been shown to be capable of transforming oral 
epithelial cells through the viral oncoproteins E6 and 
E7. The E6 protein induces degradation of p53 through 
ubiquitin-mediated proteolysis, leading to substantial 
loss of p53 activity. The usual function of p53 is to 
arrest cells in G1 or induce apoptosis to allow host 
DNA to be repaired. E6-expressing cells are not 
capable of this p53-mediated response to DNA damage 
and, hence, are susceptible to genomic instability. The 
E7 protein binds and inactivates the retinoblastoma 
tumor suppressor gene product pRB, causing the cell to 
enter S-phase, leading to cell cycle disruption. This 
functional inactivation of pRB also results in a 
reciprocal overexpression of p16 protein. By 
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immunohistochemistry, most HPV-positive HNSCCs 
show p16 overexpression (Marur et al., 2010) (Fig. 9). 
The combination of low EGFR and high p16 
expression has been shown to highly correlate with 
better clinical outcome compared with high EGFR 
expression and low HPV titer or high EGFR and low 
p16 expression (Kumar et al., 2008). P16 expression in 
oropharyngeal SCCs has also been associated with 
longer survival times regardless of HPV status (Lewis 
et al., 2010). 
The best method for HPV detection is still 
controversial. PCR-based detection of HPV E6 
oncogene expression in frozen samples is generally 
regarded as the gold standard but in situ hybridization 
is also commonly used. P16 immunohistochemistry 
could serve as a potential surrogate marker (Marur et 
al., 2010). 
As mentioned above, HPV-positive HNSCCs are 
typically TP53 wild-type. There also seems to be an 




Some precursor lesions are self-limiting and reversible 
(particularly if apparent etiologic factors are removed), 
others persist and some progress to SCC. The 
likelihood of malignant change directly relates to the 
severity of dysplasia. However, it is clear that 
malignancy can develop from any grade of dysplasia or 
even from morphologically normal epithelium. 
Dysplastic lesions classified as moderate to severe hav  
an 11% rate of malignant transformation. Diagnosis f 
precursor lesions implies a need for close follow-up 
and complete excision. Patients with carcinoma in situ 
require more extensive management (Thompson, 
2006). 
Dysplastic lesions are frequently found in the surgical 
margins of invasive SCC, meaning such lesions can 
remain in the patient. These unresected fields act as an 
important source of local recurrences and second 
primary tumors that often occur in patients treated for 
HNSCC. 
Invasive squamous cell carcinoma 
The prognosis for patients with HNSCC is determined 
by the stage at presentation, established based on the 
extent of the tumor, as well as the presence of lymph-
node metastases and distant metastases. About one 
third of patients presents with early-stage disease, 
whereas two thirds present with advanced cancer with
lymph node metastases (Jemal et al., 2007). Early-stage 
tumors are treated with surgery or radiotherapy and
have a favorable prognosis. The standard of care for 
advanced tumors is surgery combined with adjuvant 
radiation therapy and/or chemotherapy. Survival 
outcomes are poor (40-50% five-year survival rates) 
and the treatment is uniformly morbid. Organ-
preservation protocols, with combined 
chemotherapy/radiation therapy and surgery for 
salvage, are increasingly performed. These protocols 
are particularly effective for young patients with a good 
performance status presenting with moderately-
advanced laryngeal or pharyngeal SCC. Several 
characteristics of patients with HNSCC have been 
linked to favorable prognosis, including non-smoker, 
minimum exposure to alcohol, good performance 
status, and absence of co-morbid disorders (Marur et 
al., 2010). Thirty-five to 55% of patients with 
advanced-stage HNSCC remain disease-free 3 years 
after standard treatment. However, locoregional 
recurrence develops in 30% to 40% of patients and 
distant metastases occur in 20% to 30% of HNSCCs 
(Forastiere et al., 2003). Locoregional recurrences often 
require a combination of surgery, radiation therapy, 
and/or chemotherapy, and metastatic disease is treated 
with chemotherapy. 
Recently, the use of targeted drugs has entered the 
field. Cetuximab is one of the most well studied 
monoclonal antibodies directed against EGFR. Binding 
of the antibody to EGFR prevents activation of the 
receptor by endogenous ligands. An overall survival 
benefit and an increased duration of locoregional 
control have been observed in advanced HNSCCs 
treated with a combination of radiation therapy and 
cetuximab, compared to radiation therapy alone 
(Bonner et al., 2006). 
It has been demonstrated that the presence and type of 
TP53 mutation is also of prognostic relevance. Several 
studies have shown a correlation between p53 mutation 
and lower response rates to chemotherapy and shorter 
overall survival times (Erber et al., 1998; Cabelgunne 
et al., 2000; Temam et al., 2000; Poeta et al., 2007). 
On the whole, survival has not markedly improved in 
recent decades because patients still frequently develop 
locoregional recurrences, distant metastases, and 
second primary tumors. Primary prevention could be 
achieved by cessation of smoking and reduction of 
alcohol consumption. 
Patients with HPV-positive HNSCC tend to be younger 
and have a lower tobacco and alcohol consumption. 
They often present at a late stage with large metastatic 
cervical lymph nodes. Histopathologically, the tumor is 
often moderately to poorly-differentiated with basaloid 
features (Gillison et al., 2000). However, HPV-positive 
HNSCCs are associated with a more favorable clinica 
outcome regardless of treatment modalities, and this 
may be related to immune surveillance to viral antigens 
(Leemans et al., 2011). Prognosis is better not only for 
patients treated with radiation therapy or concomitant 
chemotherapy/radiation therapy but also for patients 
treated with surgery alone (Lassen et al., 2009; Fischer 
et al., 2010). In patients with oropharyngeal SCC 
treated with surgery, the 5-year survival rates for p16-
negative and p16-positive patients were 26.8% and 
57.1%, respectively (Lassen et al., 2009). In another 
study, patients with HPV-positive oropharyngeal SCC 
had a 58% reduction in the risk of death (Ang et al., 
2010). The better prognosis associated with HPV-statu  
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has also been observed in high-grade basaloid SCCs of 
the oropharynx (Thariat et al., 2010). Most studies 
confirm that HPV is one of the most important 
independent prognostic factors in HNSCC. However, 
only the rate of locoregional recurrence, but not that of 
distant disease, is diminished in patients with HPV-
positive SCC. Increased sensitivity to chemotherapy 
and radiotherapy in HPV-positive oropharyngeal 
cancer may be related to absence of exposure to 
tobacco and presence of functional p53 protein. 
Increased survival of patients with HPV-positive SCC 
may be in part attributable to absence of dysplastic 
fields related to tobacco and alcohol exposure. So, 
HPV-status of HNSCC is a prognostic factor for 
progression-free and overall survival and might also be 
a predictive factor. Use of HPV vaccines against 
infection and therapeutic vaccines in the adjuvant 
setting for locoregional recurrence and distant disease 
should be assessed in this form of HNSCC. 
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